Vanda Pharmaceuticals (VNDA) Interest & Investment Income (2010 - 2023)

Vanda Pharmaceuticals (VNDA) reported Interest & Investment Income of -$51000.0 for Q4 2023, down 151.52% sequentially from $99000.0 in Q4 2011.

Vanda Pharmaceuticals (VNDA) Interest & Investment Income (2010 - 2023) Analysis & Trends

Vanda Pharmaceuticals (VNDA) has 3 years of Interest & Investment Income data on file, last reported at -$51000.0 in Q4 2023.

For the quarter ending Q4 2023, Interest & Investment Income changed N/A year-over-year to -$51000.0; the trailing twelve-month figure through Dec 2023 stood at -$51000.0 (changed N/A YoY), and the FY2023 full-year result was -$51000.0, changed N/A from the prior year.
Interest & Investment Income eased to -$51000.0 in Q4 2023, from $99000.0 in the prior quarter.
In the past five years, Interest & Investment Income ranged from a high of -$51000.0 in Q4 2023 to a low of -$51000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int & Inv Inc (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	27.66 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	114.80 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-65.80 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	48.00 Mn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	19.51 Mn
10	Vanda Pharmaceuticals	310.98 Mn	108.67 Mn	48.56 Mn	-

Download Data